Roche reintroduces recalled eye implant in US
Genentech, a unit of Roche Group , said on Monday it has reintroduced its ocular implant, Susvimo, in the United States, following the end of a voluntary recall.
Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe
The FDA approves Roche's (RHHBY) Vabysmo prefilled syringe for treating three retinal conditions that can cause blindness.
Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals
Roche (RHHBY) announces that its mid to late-stage lung cancer study evaluating the tiragolumab combination therapy compared with Keytruda fails to meet primary endpoints.
Roche to halt trial in latest setback for lung cancer immunotherapy
Roche will end a lung cancer trial testing its new immunotherapy after the drug did not show a benefit over established treatment Keytruda by Merck & Co , casting further doubt on the drug candidate pioneered by the Swiss company.
Roche (RHHBY) Gets Positive CHMP Recommendation for Its Drugs
Roche (RHHBY) gets CHMP recommendation for a label expansion of ophthalmology drug Vabysmo (faricimab) and PiaSky (crovalimab) for the treatment of paroxysmal nocturnal haemoglobinuria.
Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod
Roche (RHHBY) obtains approval for the subcutaneous formulation of relapsing multiple sclerosis drug Ocrevus in Europe. In addition, a review of the company's MAA for gene therapy, Elevidys, is also underway.
Will Roche Stock Rebound To Its 2022 Highs Of $50?
The stock price of Roche (OTCMKTS: RHHBY) trades at $35 per share, about 33% below its peak level of over $53 seen in April 2022. In contrast, its peer Bristol Myers Squibb stock (NYSE: BMY) saw a 48% decline over this period.
US FDA approves Roche's drug for a chronic blood disorder
The U.S. Food and Drug Administration on Thursday approved Roche's drug for a chronic blood disorder, the Swiss drugmaker said.
Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics
Roche (RHHBY) gets exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million.
More Of The Same Isn't Good Enough For Roche
Roche continues to face challenges tied to lackluster revenue and profit outlook, questionable pipeline, and an underperforming diagnostics business. Roche spends aggressively on its pipeline (R&D and M&A) and is more successful than peers in converting R&D to revenue by some metrics, but trailing growth rates are quite lackluster. If key pipeline candidates like tiragolumab, prasinezumab, and RG6631 come through, Roche could see revenue and earnings reacceleration.
Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
Roche's (RHHBY) Columvi significantly extends survival in patients with relapsed or refractory diffuse large B-cell lymphoma in the phase III STARGLO study.
Roche (RHHBY) NSCLC Drug Alecensa Gets EC Nod for Label Expansion
Roche's (RHHBY) Alecensa gets the European Commission's approval as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer.
